Skip to content

A clinical study to evaluate the the Anabolic Efficacy of PRP-02 in Healthy Human Adults.

A Prospective, Single Arm, Open-label Clinical Study to Evaluate the Anabolic Efficacy of PRP-02 in Healthy Adults. - Nil

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068758
Enrollment
30
Registered
2024-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: PRP-02: 2 scoops mixed with buttermilk or skimmed milk or water and administered 10 minutes before all the 3 major meals Control Intervention1: Not Applicable: Not Applicable

Sponsors

Amway Global Services India (AGSI)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy vegetarian, adult male and female subjects, aged 18 to 45 years (both inclusive) 2.Subjects who are not taking any supplements with anabolic agents (muscle building) and/or protein powder in the past 4 weeks. 3.Subjects who have a habitual protein intake of less than or equal to 0.8 g/kg/day based on a food frequency questionnaire 4.Subjects with Body mass index (BMI) between 19-24.9 (kg/m2) with a stable weight over the past 3 months 5.Females of childbearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test at screening 6.Subjects willing to adhere with their routine diet, physical activity, and general lifestyle throughout the study. 7.Subjects who are able to understand the benefits and risks of the study protocol, follow the protocol and come for follow-up visits. 8.Must be willing and able to give informed consent and comply with the study procedures.

Exclusion criteria

Exclusion criteria: 1.Subjects diagnosed with Type 1 and 2 diabetes mellitus 2.Subjects currently on medication/ HRT (Hormone Replacement Therapy) 3.Subjects with musculoskeletal disorders that make it difficult to exercise 4.Women in the reproductive age group not willing to use standard contraceptive measures. 5.Subjects with history of oEndocrine hypothalamic- pituitary disease, women with PCOS, adrenal disorder, hypothyroidism oChronic kidney disease, oRenal stones, oLiver dysfunction (with elevated enzyme levels), oEating disorders, oChronic gastrointestinal disorders oInflammatory bowel disease (IBD) or celiac disease, oMetabolic disorders like hypertension, cardiovascular diseases - that might impair the outcomes oMalignancy which is currently active or in remission for less than five years after last treatment 6.Subjects with unstable weight (± 5 % fluctuation in their body weight for past 3 months at study entry) 7.Subjects who have undergone a surgical procedure within 1 month of signing informed consent and currently participating or has participated in a study with an investigational drug or device 8.Subjects who maybe allergic to soy or wheat or pea. 9.Known HIV or Hepatitis B positive or any other immuno-compromised state 10.Pregnant and lactating women 11.Currently participating or having participated in another clinical trial during the last 30 days prior to screening or are likely to simultaneously participate in another clinical study. 12.Subjects who are doubtful to comply with study procedures for mental, psychological or social reasons. 13.Subjects who are not willing to sign the informed consent and follow the study protocol. 14.Any additional condition(s) that in the Investigators opinion that may interfere with subject treatment, assessment or compliance with the protocol and would warrant exclusion from the study or prevent the subject from completing the study.

Design outcomes

Primary

MeasureTime frame
Change in muscle strength including handgrip strength, Pectoral strength and Quadriceps strengthTimepoint: Baseline, Day 14, Day 28

Secondary

MeasureTime frame
Biomarkers and Overall SafetyTimepoint: Baseline, Day 14, Day 28

Countries

India

Contacts

Public ContactJestin V Thomas

Leads Clinical Research and Bio Services Pvt.Ltd

jestin.leadsclinbio@gmail.com9845125293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026